Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers

NCT03749460 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03749460
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03749460 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers
Lead sponsor
University of Washington
Phase
Phase 1/2
Overall status
Completed
Start date
January 15, 2019
Completion date
November 5, 2023
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic malignant neoplasm in the bone, metastatic malignant neoplasm in the lung, salivary gland carcinoma, stage iv major salivary gland cancer ajcc v8, stage iva major salivary gland cancer ajcc v8, stage ivb major salivary gland cancer ajcc v8, stage ivc major salivary gland cancer ajcc v8